|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400081792 |
|
最近更新日期: Date of Last Refreshed on: |
2024-09-26 17:35:15 |
|
注册时间: Date of Registration: |
2024-03-12 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
比较无创胚胎植入前遗传学检测与传统胚胎植入前遗传学检测技术的累积活产率:一项多中心、随机、对照临床研究 |
|
Public title: |
Cumulative Live Birth Rate After Non-invasive Preimplantation Genetic Testing for Aneuploidy Versus Conventional Preimplantation Genetic Testing for Aneuploidy: A Pragmatic Randomized Controlled Clinical Trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
比较无创胚胎植入前遗传学检测与传统胚胎植入前遗传学检测技术的累积活产率:一项多中心、随机、对照临床研究 |
|
Scientific title: |
Cumulative Live Birth Rate After Non-invasive Preimplantation Genetic Testing for Aneuploidy Versus Conventional Preimplantation Genetic Testing for Aneuploidy: A Pragmatic Randomized Controlled Clinical Trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
路瑶 |
研究负责人: |
孙贇 |
|
Applicant: |
Lu Yao |
Study leader: |
Sun Yun |
|
申请注册联系人电话: Applicant telephone: |
+86 137 9531 3401 |
研究负责人电话:
Study leader's |
+86 136 0163 4278 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yaoluinrenji@163.com |
研究负责人电子邮件: Study leader's E-mail: |
syun163@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海浦东新区灵山路845号 |
研究负责人通讯地址: |
上海浦东新区灵山路845号 |
|
Applicant address: |
845 Lingshan Road, Pudong New District, Shanghai |
Study leader's address: |
845 Lingshan Road, Pudong New District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
200135 |
研究负责人邮政编码: Study leader's postcode: |
200135 |
|
申请人所在单位: |
上海交通大学医学院附属仁济医院 |
||
|
Applicant's institution: |
Renji Hospital, Shanghai Jiaotong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属仁济医院 |
||
|
Affiliation of the Leader: |
Renji Hospital, Shanghai Jiaotong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LY2023-250-B; LY2023-250-B-AMD-01; LY2023-250-B-AMD-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属仁济医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Renji Hospital, Shanghai Jiaotong University School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-12-14 00:00:00 | ||
|
伦理委员会联系人: |
陆麒 |
||
|
Contact Name of the ethic committee: |
Lu Qi |
||
|
伦理委员会联系地址: |
上海浦建路160号 |
||
|
Contact Address of the ethic committee: |
160 Pujian Road, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6838 3364 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海交通大学医学院附属仁济医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市浦东新区灵山路845号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
845 Lingshan Road, Pudong New District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海亿康医学检验所有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Yikon Genomics Co., Ltd |
||||||||||||||||||||||
|
研究疾病: |
不孕症 |
||||||||||||||||||||||
|
Target disease: |
Infertility |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
比较无创胚胎植入前遗传学检测(non-invasive preimplantation genetic testing for aneuploidy, niPGT-A)相比传统胚胎植入前遗传学检测(PGT-A)对于高龄女性助孕的累积活产率。 |
||||||||||||||||||||||
|
Objectives of Study: |
To compare the cumulative live birth rate after non-invasive preimplantation genetic testing for aneuploidy (niPGT-A) versus conventional preimplantation genetic testing for aneuploidy (PGT-A) in women with advanced age. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1) 女方取卵时年龄≥35岁 2) 拟行PGT-A助孕 3) 获得D5/D6可移植囊胚≥1枚 4) 自愿签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
1) Women aged ≥35 years old when oocytes were retrieved; 2) Women who intend to undergo PGT-A; 3) Women who have ≥1 D5/ D6 blastocysts; 4) Voluntary signing of informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1) 夫妻双方任何一方染色体异常(多态性除外) 2) 拟行胚胎植入前染色体结构异常检测(PGT-SR)或胚胎植入前单基因检测(PGT-M)的患者 3) 使用供精或供卵助孕的患者 4) 明确的影响宫腔形态或内膜容受性疾病,如未经治疗的子宫畸形(纵膈子宫、单角子宫、双子宫等) 5) 有妊娠禁忌症或辅助生育技术禁忌症者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Chromosomal abnormalities in either spouse (excluding polymorphism) 2) PGT-M or PGT-SR cycles; 3) Donor sperm or donor egg cycles; 4) Women who have been diagnosed with diseases affecting uterine cavity morphology or endometrial receptivity, such as untreated uterine malformations (such as mediastinal uterus, unicorn uterus, bilateral uterus, etc.); 5) Women with medical contraindications to assisted reproductive technology and/or pregnancy. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-09-30 00:00:00至 To 2028-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-09-30 00:00:00 至 To 2028-07-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
数据协调中心(DCC)生成随机分组序列表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Data coordinator center will generate random number sequence |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
开放 |
|
Blinding: |
Open label |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
我们将利用临床试验公共管理平台实现数据共享, http://www.medresman.org.cn |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
We will share data vis clinical trial database, http://www.medresman.org.cn |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
我们将利用临床试验公共管理平台收集数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
We will use the public clinical trial database, i.e. Resman database to collect data |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |